Substance use disorders during the COVID-19 pandemic: looking for new innovative approaches
暂无分享,去创建一个
[1] N. Scherbaum,et al. COVID-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis , 2021, Brain sciences.
[2] S. Boujraf,et al. The Impact of Stigma on Treatment Services for People With Substance Use Disorders During the COVID-19 Pandemic—Perspectives of NECPAM Members , 2021, Frontiers in Psychiatry.
[3] J. Cousijn,et al. For better or for worse? A pre-post exploration of the impact of the COVID-19 lockdown on cannabis users. , 2021, Addiction.
[4] C. Gambelunghe,et al. Changes in Drug Use Patterns during the COVID-19 Pandemic in Italy: Monitoring a Vulnerable Group by Hair Analysis , 2020, International journal of environmental research and public health.
[5] F. Schifano,et al. Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach , 2021, Frontiers in Psychiatry.
[6] W. Hall,et al. Cannabis and COVID-19: Reasons for Concern , 2020, Frontiers in Psychiatry.
[7] M. Torrens,et al. Editorial: New Trends of Substance Abuse: Looking for New Psychotropic Effects of Chem Sex Drugs, Cognitive Enhancers, and New Psychoactive Substances , 2020, Frontiers in Psychiatry.
[8] A. Dopp,et al. Combatting the Stigma of Addiction - The Need for a Comprehensive Health System Approach. , 2020, NAM perspectives.
[9] G. Ricci,et al. Consequences of COVID-19 Lockdown on the Misuse and Marketing of Addictive Substances and New Psychoactive Substances , 2020, Frontiers in Psychiatry.
[10] M. Camacho-Rivera,et al. The COVID-19 cannabis health study: Results from an epidemiologic assessment of adults who use cannabis for medicinal reasons in the United States , 2020, Journal of addictive diseases.
[11] E. Onaivi,et al. Cannabis for COVID-19: can cannabinoids quell the cytokine storm? , 2020, Future science OA.
[12] S. Dubey,et al. COVID-19 and addiction , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[13] F. Pechansky,et al. The COVID-19 pandemic and its impact on substance use: Implications for prevention and treatment , 2020, Psychiatry Research.
[14] N. Volkow. Stigma and the Toll of Addiction. , 2020, The New England journal of medicine.
[15] S. Pichini,et al. Development and validation of fast UHPLC-MS/MS screening method for 87 NPS and 32 other drugs of abuse in hair and nails: application to real cases , 2020, Analytical and Bioanalytical Chemistry.
[16] R. Pacifici,et al. Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use. , 2020, Therapeutic drug monitoring.
[17] R. Bruno,et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses , 2019, The Lancet.
[18] S. Zaami. New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard. , 2019, European review for medical and pharmacological sciences.
[19] R. Pacifici,et al. The value of toxicological and forensic analyses in the global challenge to health risks caused by new psychoactive substances. , 2019, European review for medical and pharmacological sciences.
[20] A. Tagliabracci,et al. Editorial: The Challenge Posed by New Synthetic Opioids: Pharmacology and Toxicology , 2019, Front. Pharmacol..
[21] T. Rosado,et al. Novel synthetic opioids – toxicological aspects and analysis , 2019, Forensic sciences research.
[22] Jacek Kopec,et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The lancet. Psychiatry.
[23] N. M. di Luca,et al. Medical use of cannabis: Italian and European legislation. , 2018, European review for medical and pharmacological sciences.
[24] S. Pichini,et al. Correlation between Blood and Oral Fluid Psychoactive Drug Concentrations and Cognitive Impairment in Driving under the Influence of Drugs , 2017, Current neuropharmacology.
[25] R. Pacifici,et al. European Drug Users at Risk from Illicit Fentanyls Mix , 2017, Front. Pharmacol..
[26] Justin Arnold,et al. Novel Psychoactive Substances and Trends of Abuse , 2017, Critical care nursing quarterly.
[27] F. Indorato,et al. The pathogenetic role of adulterants in 5 cases of drug addicts with a fatal outcome. , 2013, Forensic science international.